This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Calabrò, A. Articles by Crepaldi, G. Search for Related Content PubMed PubMed Citation Articles by Calabrò, A. Articles by Crepaldi, G. Social Bookmarking                         What's this?

Clinical Assessment of Low Molecular Weight Heparin Effects in Peripheral Vascular Disease

Institute of Internal Medicine, Chair of I Medical Pathology, University of Padua, Italy

Francesco Piarulli

Institute of Internal Medicine, Chair of I Medical Pathology, University of Padua, Italy

Daniele Milan

Institute of Internal Medicine, Chair of I Medical Pathology, University of Padua, Italy

Alberto Rossi

Institute of Internal Medicine, Chair of I Medical Pathology, University of Padua, Italy

Giovanna Coscetti

Institute of Internal Medicine, Chair of I Medical Pathology, University of Padua, Italy

Gaetano Crepaldi

Institute of Internal Medicine, Chair of I Medical Pathology, University of Padua, Italy

This study was carried out, using the double-blind method vs placebo, on 36 patients suffering from stage II peripheral vascular disease (PVD) according to Leriche, to check the clinical and hemorrheologic effects of the administration of a new low molecular weight heparin (LMWH). After a one-month washout period, the patients were randomly assigned either to the group treated with the LMWH (15,000 aXaU/day sc) or to the group treated with indistinguishable placebo.

At the start of the study and after three and six months of treatment, clini cal, instrumental, and laboratory tests were performed to assess local and sys temic efficacy and tolerance.

The LMWH under study caused a statistically significant increase in claudi cation time, with a parallel increase in the absolute claudication distance and in the interval free of pain. The drug also led to a significant increase in activated partial thromboplastin time, the values of which, however, remained within the normal limits, and to a marked reduction in blood viscosity. No significant vari ation was observed in the tolerability parameters in the two treatment groups, and no local or systemic adverse reactions occurred.

Angiology, Vol. 44, No. 3, 188-195 (1993)
DOI: 10.1177/000331979304400304


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?